Answers are grounded in this paper and cite their sources.
Cross-sectional study shows endothelin-2 correlates with uric acid and inflammatory markers in chronic kidney disease, suggesting it may serve as a biomarker.
Chronic kidney disease (CKD) is associated with chronic inflammation and metabolic dysregulation. While endothelin-1 (ET-1) has been extensively studied, the role of endothelin-2 (ET-2) in CKD remains poorly understood. This cross-sectional study included 76 participants, 12 healthy controls and 64 CKD patients, stratified into three groups based on estimated glomerular filtration rate (eGFR): Group 1 (eGFR ≥ 90 mL/min/1.73 m2), Group 2 (eGFR 45–89 mL/min/1.73 m2), and Group 3 (eGFR 15–44 mL/min/1.73 m2). Serum concentrations of ET-1, ET-2, ET-3, uric acid (UA), and inflammatory markers (hsCRP and IL-6) were measured. ET-2 levels were significantly higher in the advanced CKD group (median 24.49 pg/mL) compared to controls (median 19.32 pg/mL; p = 0.030). No significant differences were observed for ET-1 or ET-3 across groups. ET-2 levels positively correlated with UA (rho = 0.243, p = 0.036), hsCRP (rho = 0.241, p = 0.039), and IL-6 (rho = 0.244, p = 0.038). These findings suggest that ET-2 may represent a potential biomarker reflecting metabolic and inflammatory dysregulation in CKD and highlight its possible relevance in disease severity assessment.
No takes yet. Share an insight, caveat, or question.
Blazhev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: